NCT04530630View on ClinicalTrials.gov

Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 9, 2020

Primary Completion Date

August 28, 2024

Study Completion Date

August 28, 2024

Conditions
HIV InfectionsRenal Transplant Rejection
Interventions
DRUG

BIC/F/TAF 50Mg-200Mg-25Mg Tablet

A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide.

Trial Locations (1)

10065

Weill Cornell Medicine, New York

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER